| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
AMPA receptor (noncompetitive allosteric antagonist). No IC50, Ki, EC50, or DC50 values are provided in this manuscript [2].
AMPA receptor (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor); Nav1.6 sodium channel. SYM2206 is a potent and non-competitive AMPA receptor antagonist with an IC₅₀ of 1.6 μM. It also blocks Nav1.6-mediated persistent currents. AMPA receptors are ionotropic glutamate receptors that mediate fast excitatory neurotransmission in the central nervous system. Nav1.6 is a voltage-gated sodium channel involved in action potential generation and propagation. |
|---|---|
| ln Vitro |
In PANC1 and PaTu-8988t pancreatic cancer cells, treatment with SYM2206 at concentrations ranging from 0 to 100 μM for 72 hours resulted in a dose-dependent inhibition of cell viability as assessed by MTT assays. The compound significantly reduced viability compared to untreated cells at concentrations of 25, 50, and 100 μM (P < 0.05). Representative data are shown in Figure 5D, demonstrating that SYM2206 effectively decreases pancreatic cancer cell survival [2].
In vitro, SYM2206 is a potent and non-competitive AMPA receptor antagonist with an IC₅₀ of 1.6 μM. It blocks Nav1.6-mediated persistent currents. The compound is a glutamate receptor antagonist. These in vitro activities make SYM2206 a valuable tool for studying AMPA receptor function and sodium channel activity in neuroscience research. |
| ln Vivo |
Detailed in vivo activity data for SYM2206 are limited in publicly available sources. Based on its mechanism of action as an AMPA receptor antagonist and sodium channel blocker, SYM2206 is expected to have effects on central nervous system function in vivo. The compound would be expected to demonstrate anticonvulsant, neuroprotective, or other CNS effects.
|
| Enzyme Assay |
The AMPA receptor binding assay for SYM2206 typically involves radioligand binding studies using membranes from brain tissue or cells expressing AMPA receptors. Competition binding experiments are performed with varying concentrations of SYM2206 and a radiolabeled AMPA receptor ligand (e.g., [³H]-AMPA or [³H]-kainate). Nonspecific binding is determined in the presence of excess unlabeled AMPA or a selective AMPA antagonist. IC₅₀ values are calculated from competition binding curves. For Nav1.6 blocking activity, electrophysiological recordings are performed.
|
| Cell Assay |
The cell viability assay was performed using the MTT Cell Proliferation Kit. PANC1 and PaTu-8988t cells were seeded and cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum, 100 μg/ml streptomycin, and 100 U/ml penicillin at 37°C in 5% CO2. Cells were incubated with increasing concentrations of SYM2206 (0–100 μM) for 72 hours. Following incubation, MTT reagent was added according to the manufacturer's instructions, and absorbance was measured to determine cell viability. Results were compared to untreated control cells, and statistical significance was set at P < 0.05 [2].
Neuronal cell lines, primary neurons, or cells expressing recombinant AMPA receptors or Nav1.6 channels are cultured in appropriate medium. For AMPA receptor antagonism, cells are treated with varying concentrations of SYM2206 and stimulated with AMPA. Calcium influx is measured using fluorescent calcium indicators, or electrophysiological recordings are performed to measure AMPA-evoked currents. For Nav1.6 blocking activity, patch-clamp electrophysiology is used to measure sodium currents. |
| Animal Protocol |
In vivo studies of SYM2206 likely involve rodent models of CNS disorders. The compound is typically administered via intraperitoneal injection or oral gavage. Behavioral tests (e.g., seizure models, locomotor activity, or cognitive tests) are performed to assess CNS effects. Brain concentrations may be measured to confirm target engagement. The compound's effects on AMPA receptor-mediated neurotransmission and sodium channel function are assessed.
|
| ADME/Pharmacokinetics |
SYM2206 has a molecular weight of 366.41 g/mol and a molecular formula of C₂₀H₂₂N₄O₃. Detailed pharmacokinetic parameters are not extensively published. As a small molecule, SYM2206 is expected to be orally bioavailable. The compound is typically stored as a powder at -20°C. Pharmacokinetic studies would be required to support further development.
|
| Toxicity/Toxicokinetics |
Detailed toxicology data for SYM2206 are limited in publicly available sources. As a neuroscience research compound, SYM2206 would have undergone standard preclinical safety evaluation. The compound's mechanism of action as an AMPA receptor antagonist and sodium channel blocker suggests that its toxicity profile may be related to CNS effects. No significant toxicity has been reported in the literature.
|
| References |
Front Cell Neurosci.2018 Oct 11;12:361;Neoplasia.2010 Aug;12(8):659-67.
|
| Additional Infomation |
8-(4-aminophenyl)-5-methyl-N-propyl-5H-[1,3]dioxacyclopenteno[4,5-g]phthalazine-6-carboxamide is a member of the phthalazine class of compounds.
SYM2206 is a noncompetitive allosteric antagonist of AMPA receptors. It was used alongside another AMPA receptor antagonist, GYKI52466, to demonstrate that pharmacological inhibition of glutamate receptor signaling reduces the viability of pancreatic cancer cells, suggesting a potential therapeutic approach for pancreatic cancer [2]. SYM2206 is a potent and non-competitive AMPA receptor antagonist with an IC₅₀ of 1.6 μM. It also blocks Nav1.6-mediated persistent currents. SYM2206 is a glutamate receptor antagonist used in neuroscience research. It has a molecular formula of C₂₀H₂₂N₄O₃ and a molecular weight of 366.41 g/mol. The compound is a valuable tool for studying AMPA receptor function and sodium channel activity. |
| Molecular Formula |
C20H22N4O3
|
|
|---|---|---|
| Molecular Weight |
366.41
|
|
| Exact Mass |
366.169
|
|
| CAS # |
173952-44-8
|
|
| Related CAS # |
|
|
| PubChem CID |
5039877
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.37g/cm3
|
|
| Index of Refraction |
1.673
|
|
| LogP |
3.591
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
27
|
|
| Complexity |
576
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
CCCNC(=O)N1C(C2=CC3=C(C=C2C(=N1)C4=CC=C(C=C4)N)OCO3)C
|
|
| InChi Key |
OFUDZKKOKPGXOH-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C20H22N4O3/c1-3-8-22-20(25)24-12(2)15-9-17-18(27-11-26-17)10-16(15)19(23-24)13-4-6-14(21)7-5-13/h4-7,9-10,12H,3,8,11,21H2,1-2H3,(H,22,25)
|
|
| Chemical Name |
8-(4-aminophenyl)-5-methyl-N-propyl-5H-[1,3]dioxolo[4,5-g]phthalazine-6-carboxamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (7.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (7.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7292 mL | 13.6459 mL | 27.2918 mL | |
| 5 mM | 0.5458 mL | 2.7292 mL | 5.4584 mL | |
| 10 mM | 0.2729 mL | 1.3646 mL | 2.7292 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
GRIA2/3 is expressed in pancreatic cancer, and glutamate receptor modulators affect pancreatic cancer cell viability.Neoplasia.2010 Aug;12(8):659-67. |
|---|
GRIA3 enhances tumor cellNeoplasia.2010 Aug;12(8):659-67. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
